National Health Research Institutes, Taiwan — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Adefovir Dipivoxil and LamivudineResearch Objective and Study End Points To evaluate the anti-HBV as well as HCC recurrence reducing effects of standard (18 months) lamivudine treatment at time of HBV reactivation with hepatitis flare up (HBV DNA \> 105 copies/mL and ALT level \> 2.0 x UNL) or prophylactic, prolong (36 months) adefovir dipivoxil therapy in post-operative HBsAg(+),\< 5 cm HCC patients, and to compare the results of who group with historical controls (T1297, HBsAg+,\< 5 cm HCC cohort),in terms of the following endpoints. 1. Primary endpoint: the 3-years recurrence rate (excluding those recur within first year). 2. Secondary endpoints: the first 2 year tumor recurrence rates the recurrence-free survival the overall survival. anti-viral efficacy, i.e. biochemical response and viral response rate. to correlate the changes of viral titer with the clinical outcome in post- operative HCC patients with adjuvant lamivudine or adefovir therapy.	Cancer	À vérifier	À vérifier	Taiwan	À vérifier
Adefovir Dipivoxil and LamivudineResearch Objective and Study End Points To evaluate the anti-HBV as well as HCC recurrence reducing effects of standard (18 months) lamivudine treatment at time of HBV reactivation with hepatitis flare up (HBV DNA \> 105 copies/mL and ALT level \> 2.0 x UNL) or prophylactic, prolong (36 months) adefovir dipivoxil therapy in post-operative HBsAg(+),\< 5 cm HCC patients, and to compare the results of who group with historical controls (T1297, HBsAg+,\< 5 cm HCC cohort),in terms of the following endpoints. 1. Primary endpoint: the 3-years recurrence rate (excluding those recur within first year). 2. Secondary endpoints: the first 2 year tumor recurrence rates the recurrence-free survival the overall survival. anti-viral efficacy, i.e. biochemical response and viral response rate. to correlate the changes of viral titer with the clinical outcome in post- operative HCC patients with adjuvant lamivudine or adefovir therapy.	Cancer	À vérifier	À vérifier	Taiwan	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Adefovir Dipivoxil and Lamivudine	Cancer	À vérifier	NCT00455091	A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma	TERMINATED

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Adefovir Dipivoxil and Lamivudine		[Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Adefovir Dipivoxil and Lamivudine		[Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].	Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Adefovir Dipivoxil and Lamivudine		Human Embryoid Body-Based Assays for Preclinical Screening of Potential Teratogenic Drugs: Antiviral Drugs for Hepatitis B Virus as Examples.	Stem cells and development